IMR Press / EJGO / Volume 26 / Issue 5 / pii/2005217

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Differential gene expression assessed by cDNA microarray analysis in breast cancer tissue under tamoxifen treatment

Show Less
1 Molecular Gynecology Laboratory, Department of Gynecology, Federal University of Silo Paulo, Paulista School of Medicinel,  Silo Paulo (Brazil)
2 Ludwig Institute for Cancer Research, Silo Paulo Branch, Silo Paulo (Brazil)
Eur. J. Gynaecol. Oncol. 2005, 26(5), 501–504;
Published: 10 October 2005
Abstract

Our purpose was to identify tamoxifen (TAM) responsive genes after 30 days of TAM treatment in tumor tissues obtained from women with breast cancer using microarray expression analysis. In our study, we identified 12 candidates to be considered as tamox­ifen-modulated genes. Among them, we selected two candidates the TEGT BI-I (testis enhanced gene transcript Bax Inhibitor-1) and the CD63 gene in order to further confirm their differential expression under tamoxifen effects. We observed that both were down-regulated in tumor tissues of patients during TAM treatment. TEGT is able to inhibit the expression of Bax, which is known to promote apoptosis. On the other hand, CD63 encodes a cell membrane protein and it seems to be involved in mechanisms of platelet activation, cell adhesion and cell motility. We therefore hypothesize that TAM would be able to modulate tumor growth by down-regulating genes involved in mechanisms such as cell cycle control, tumor invasion and metastasis.

Keywords
cDNA microarray analysis
Breast cancer
Tamoxifen
Share
Back to top